- Home
- PGRE vs CRGX Comparison
PGRE vs CRGX Comparison
Compare PGRE & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- CRGX
- Stock Information
- Founded
- PGRE 1978
- CRGX 2021
- Country
- PGRE United States
- CRGX United States
- Employees
- PGRE N/A
- CRGX N/A
- Industry
- PGRE Real Estate Investment Trusts
- CRGX
- Sector
- PGRE Real Estate
- CRGX
- Exchange
- PGRE Nasdaq
- CRGX Nasdaq
- Market Cap
- PGRE 1.3B
- CRGX 190.0M
- IPO Year
- PGRE 2014
- CRGX 2023
- Fundamental
- Price
- PGRE $6.67
- CRGX $4.59
- Analyst Decision
- PGRE Hold
- CRGX Hold
- Analyst Count
- PGRE 4
- CRGX 7
- Target Price
- PGRE $5.38
- CRGX $5.33
- AVG Volume (30 Days)
- PGRE 3.3M
- CRGX 1.9M
- Earning Date
- PGRE 07-30-2025
- CRGX 08-11-2025
- Dividend Yield
- PGRE N/A
- CRGX N/A
- EPS Growth
- PGRE N/A
- CRGX N/A
- EPS
- PGRE N/A
- CRGX N/A
- Revenue
- PGRE $711,729,000.00
- CRGX N/A
- Revenue This Year
- PGRE $2.74
- CRGX $57.81
- Revenue Next Year
- PGRE N/A
- CRGX N/A
- P/E Ratio
- PGRE N/A
- CRGX N/A
- Revenue Growth
- PGRE 49.28
- CRGX N/A
- 52 Week Low
- PGRE $3.75
- CRGX $3.00
- 52 Week High
- PGRE $6.72
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- PGRE 69.05
- CRGX 61.56
- Support Level
- PGRE $5.96
- CRGX $4.32
- Resistance Level
- PGRE $6.72
- CRGX $4.63
- Average True Range (ATR)
- PGRE 0.19
- CRGX 0.16
- MACD
- PGRE 0.00
- CRGX 0.04
- Stochastic Oscillator
- PGRE 86.18
- CRGX 76.44
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.